Understand the source comparison
The NNMT Pathway vs GLP-1 Receptor Mechanisms
5-Amino-1MQ and GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) both produce fat loss in research models—but through entirely different biological cascades. GLP-1 agonists bind to GLP-1 receptors in the hypothalamus and gastrointestinal tract,
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 5-Amino-1MQ and GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) both produce fat loss in research models—but through entirely different biological cascades. GLP-1 agonists bind to GLP-1 receptors in the hypothalamus and gastrointestinal tract, slowing gastric emptying and extending postprandial satiety hormone elevation (GLP-1, PYY). The result is reduced caloric intake driven by delayed ghrelin rebound—fat loss follows as a downstream effect of sustained caloric deficit.
- 5-Amino-1MQ operates upstream of appetite regulation entirely. NNMT is expressed in adipose tissue, liver, and skeletal muscle—it methylates nicotinamide (a precursor to NAD+) into N-methylnicotinamide, which the body excretes. When NNMT is overactive, NAD+ availability drops, SIRT1 and AMPK activation decline, and cells default to glucose storage rather than fat oxidation. 5-Amino-1MQ blocks NNMT, allowing NAD+ levels to rise and activating the same pathways that caloric restriction and fasting trigger—but without requiring dietary reduction.
- In practical research terms: GLP-1 agonists require caloric deficit to produce fat loss. 5-Amino-1MQ shifts substrate utilization independent of intake. The Cell Metabolism study found that 5-amino-1MQ-treated mice lost 7% body weight over 11 days despite ad libitum feeding—no appetite suppression was observed. GLP-1 protocols, by contrast, lose efficacy if caloric intake compensates for appetite changes. That makes 5-amino-1MQ uniquely suited for research examining metabolic flexibility independent of energy balance—a question GLP-1 studies can't cleanly address.